CO2017010510A2 - Tableta de ribociclib - Google Patents
Tableta de ribociclibInfo
- Publication number
- CO2017010510A2 CO2017010510A2 CONC2017/0010510A CO2017010510A CO2017010510A2 CO 2017010510 A2 CO2017010510 A2 CO 2017010510A2 CO 2017010510 A CO2017010510 A CO 2017010510A CO 2017010510 A2 CO2017010510 A2 CO 2017010510A2
- Authority
- CO
- Colombia
- Prior art keywords
- ribociclib
- tablet
- coating
- present disclosure
- coated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562148240P | 2015-04-16 | 2015-04-16 | |
| PCT/IB2016/052136 WO2016166703A1 (en) | 2015-04-16 | 2016-04-14 | Ribociclib tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017010510A2 true CO2017010510A2 (es) | 2018-03-20 |
Family
ID=55806565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0010510A CO2017010510A2 (es) | 2015-04-16 | 2017-10-13 | Tableta de ribociclib |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US10799506B2 (https=) |
| EP (3) | EP3283058B1 (https=) |
| JP (1) | JP2018514523A (https=) |
| KR (2) | KR102750931B1 (https=) |
| CN (2) | CN107530292B (https=) |
| AR (1) | AR104257A1 (https=) |
| AU (5) | AU2016248017A1 (https=) |
| BR (1) | BR112017021283A2 (https=) |
| CA (1) | CA2982425C (https=) |
| CL (1) | CL2017002593A1 (https=) |
| CO (1) | CO2017010510A2 (https=) |
| DK (2) | DK3283058T3 (https=) |
| EA (1) | EA201792290A1 (https=) |
| EC (1) | ECSP17075052A (https=) |
| ES (2) | ES2938261T3 (https=) |
| FI (2) | FI3283058T3 (https=) |
| HR (2) | HRP20260123T1 (https=) |
| HU (1) | HUE061213T2 (https=) |
| IL (1) | IL254818A0 (https=) |
| LT (1) | LT4197530T (https=) |
| MX (1) | MX2017013350A (https=) |
| PE (1) | PE20180035A1 (https=) |
| PH (1) | PH12017501820A1 (https=) |
| PL (2) | PL4197530T3 (https=) |
| PT (2) | PT4197530T (https=) |
| RS (1) | RS67697B1 (https=) |
| SG (1) | SG11201708084PA (https=) |
| SI (2) | SI3283058T1 (https=) |
| TN (1) | TN2017000422A1 (https=) |
| TW (1) | TW201642864A (https=) |
| WO (1) | WO2016166703A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102529049B1 (ko) | 2013-08-14 | 2023-05-08 | 노파르티스 아게 | 암의 치료를 위한 조합 요법 |
| HUE061213T2 (hu) | 2015-04-16 | 2023-05-28 | Novartis Ag | Ribociklib tabletta |
| CA3048036A1 (en) | 2018-07-02 | 2020-01-02 | Apotex Inc | Crystalline form of ribociclib succinate |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CR20220342A (es) | 2019-12-16 | 2023-01-23 | Lunella Biotech Inc | Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6 |
| MX2022007487A (es) | 2019-12-16 | 2022-08-04 | Lunella Biotech Inc | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. |
| CA3187241A1 (en) * | 2020-08-03 | 2022-02-10 | Krishna Murthy Bhavanasi | Pharmaceutical compositions comprising ribociclib |
| WO2022071787A1 (es) * | 2020-09-29 | 2022-04-07 | Laboratorios Silanes S.A. De C.V. | Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares |
| WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
| CN117396208A (zh) | 2021-07-16 | 2024-01-12 | 达纳－法伯癌症研究所公司 | 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法 |
| TWI908143B (zh) | 2022-01-25 | 2025-12-11 | 瑞士商諾華公司 | 瑞博西尼藥物組成物用於治療癌症之用途 |
| WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
| EP4626890A1 (en) | 2022-12-01 | 2025-10-08 | KRKA, d.d., Novo mesto | Ribociclib salts and formulations thereof |
| KR20250163966A (ko) | 2023-03-27 | 2025-11-21 | 노파르티스 아게 | 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법 |
| TW202602868A (zh) | 2024-04-15 | 2026-01-16 | 瑞士商諾華公司 | 瑞波西利的藥物組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5428812A (en) * | 1977-08-09 | 1979-03-03 | Yoshitomi Pharmaceut Ind Ltd | Preparation of coated tablet |
| HU225964B1 (en) * | 1994-07-12 | 2008-01-28 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| GB9414045D0 (en) | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
| US6448323B1 (en) * | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
| ES2522346T3 (es) | 2008-08-22 | 2014-11-14 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de CDK |
| US8871263B2 (en) * | 2009-09-24 | 2014-10-28 | Mcneil-Ppc, Inc. | Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder |
| AR083797A1 (es) | 2010-11-10 | 2013-03-20 | Novartis Ag | Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos |
| EA025033B1 (ru) * | 2011-02-11 | 2016-11-30 | Уиста Лэборэтэриз Лтд. | Диаминиевые соли фенотиазина и их применение |
| PT2872482T (pt) * | 2012-07-13 | 2020-09-22 | Oncternal Therapeutics Inc | Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm) |
| EP2742940B1 (en) * | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
| US9867825B2 (en) * | 2012-12-20 | 2018-01-16 | Novartis Ag | Pharmaceutical combination comprising binimetinib |
| UA118846C2 (uk) * | 2013-03-21 | 2019-03-25 | Новартіс Аг | Комбінована терапія |
| EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
| HUE061213T2 (hu) | 2015-04-16 | 2023-05-28 | Novartis Ag | Ribociklib tabletta |
| CN109953966A (zh) * | 2017-12-26 | 2019-07-02 | 天津耀辰实业发展有限公司 | 一种含有瑞博西尼的药物组合物及其制备方法 |
| JP7347388B2 (ja) | 2020-09-25 | 2023-09-20 | 信越化学工業株式会社 | 紫外線硬化型有機変性シリコーン組成物および硬化物 |
-
2016
- 2016-04-14 HU HUE16718020A patent/HUE061213T2/hu unknown
- 2016-04-14 PL PL22203730.1T patent/PL4197530T3/pl unknown
- 2016-04-14 SI SI201631661T patent/SI3283058T1/sl unknown
- 2016-04-14 CN CN201680022122.8A patent/CN107530292B/zh active Active
- 2016-04-14 US US15/564,534 patent/US10799506B2/en active Active
- 2016-04-14 FI FIEP16718020.7T patent/FI3283058T3/fi active
- 2016-04-14 KR KR1020177029433A patent/KR102750931B1/ko active Active
- 2016-04-14 EP EP16718020.7A patent/EP3283058B1/en active Active
- 2016-04-14 PT PT222037301T patent/PT4197530T/pt unknown
- 2016-04-14 MX MX2017013350A patent/MX2017013350A/es unknown
- 2016-04-14 SG SG11201708084PA patent/SG11201708084PA/en unknown
- 2016-04-14 AU AU2016248017A patent/AU2016248017A1/en not_active Abandoned
- 2016-04-14 AR ARP160101012A patent/AR104257A1/es unknown
- 2016-04-14 PT PT167180207T patent/PT3283058T/pt unknown
- 2016-04-14 HR HRP20260123TT patent/HRP20260123T1/hr unknown
- 2016-04-14 EA EA201792290A patent/EA201792290A1/ru unknown
- 2016-04-14 SI SI201631943T patent/SI4197530T1/sl unknown
- 2016-04-14 RS RS20260107A patent/RS67697B1/sr unknown
- 2016-04-14 PE PE2017002096A patent/PE20180035A1/es unknown
- 2016-04-14 DK DK16718020.7T patent/DK3283058T3/da active
- 2016-04-14 TN TNP/2017/000422A patent/TN2017000422A1/en unknown
- 2016-04-14 ES ES16718020T patent/ES2938261T3/es active Active
- 2016-04-14 KR KR1020257000051A patent/KR20250009572A/ko active Pending
- 2016-04-14 DK DK22203730.1T patent/DK4197530T3/da active
- 2016-04-14 WO PCT/IB2016/052136 patent/WO2016166703A1/en not_active Ceased
- 2016-04-14 JP JP2017553915A patent/JP2018514523A/ja active Pending
- 2016-04-14 EP EP25194967.3A patent/EP4620458A3/en active Pending
- 2016-04-14 HR HRP20230053TT patent/HRP20230053T1/hr unknown
- 2016-04-14 FI FIEP22203730.1T patent/FI4197530T3/fi active
- 2016-04-14 CA CA2982425A patent/CA2982425C/en active Active
- 2016-04-14 BR BR112017021283A patent/BR112017021283A2/pt not_active Application Discontinuation
- 2016-04-14 LT LTEP22203730.1T patent/LT4197530T/lt unknown
- 2016-04-14 PL PL16718020.7T patent/PL3283058T3/pl unknown
- 2016-04-14 EP EP22203730.1A patent/EP4197530B1/en active Active
- 2016-04-14 CN CN202211237232.XA patent/CN115554257A/zh active Pending
- 2016-04-14 ES ES22203730T patent/ES3062263T3/es active Active
- 2016-04-15 TW TW105111921A patent/TW201642864A/zh unknown
-
2017
- 2017-10-01 IL IL254818A patent/IL254818A0/en unknown
- 2017-10-04 PH PH12017501820A patent/PH12017501820A1/en unknown
- 2017-10-13 CL CL2017002593A patent/CL2017002593A1/es unknown
- 2017-10-13 CO CONC2017/0010510A patent/CO2017010510A2/es unknown
- 2017-11-10 EC ECIEPI201775052A patent/ECSP17075052A/es unknown
-
2019
- 2019-03-20 AU AU2019201929A patent/AU2019201929B2/en active Active
-
2020
- 2020-08-26 US US17/003,771 patent/US20200390771A1/en not_active Abandoned
- 2020-10-06 AU AU2020250190A patent/AU2020250190A1/en not_active Abandoned
-
2022
- 2022-06-08 US US17/805,956 patent/US12064434B2/en active Active
- 2022-08-08 AU AU2022215155A patent/AU2022215155B2/en active Active
-
2024
- 2024-02-27 US US18/588,259 patent/US20250090531A1/en active Pending
- 2024-10-31 AU AU2024227794A patent/AU2024227794A1/en active Pending
- 2024-12-11 US US18/977,210 patent/US20250134893A1/en active Pending
- 2024-12-11 US US18/977,228 patent/US12419894B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017010510A2 (es) | Tableta de ribociclib | |
| EP3652650A4 (en) | TECHNIQUES FOR MANAGING ACCESS TO A HARDWARE ACCELERATOR MEMORY | |
| BR112016013502A2 (pt) | unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol. | |
| BR112018013462A2 (pt) | métodos de fabricação de aditivo para adesivos e artigos adesivos | |
| EP2986681A4 (en) | An aqueous coating composition | |
| BR112016012615A8 (pt) | sistemas, e kit | |
| DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
| BR112015032445A2 (pt) | componente semicondutor orgânico | |
| CL2016000009A1 (es) | Tratamiento de rosacea papulopustular con ivermectina. | |
| EP3450435A4 (en) | SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE IN POSITION 5 HAVING AN AMPK ACTIVATION ACTION | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| PH12016500626B1 (en) | Film coated tablet containing choline alfoscerate and process for preparing the same | |
| CL2016002338A1 (es) | Uso de un compuesto que es ácido r-2-4-2-etoxi-3-4-trifluorometilfenoxipropil-tio-2-metilfenoxi acético, para el tratamiento de una enfermedad colestásica intrahepática . | |
| EP3630113A4 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A PDE9 INHIBITOR | |
| PT3516710T (pt) | Camada de barreira eletroativa limitadora da difusão para um componente optoeletrónico | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| BR112017011658A2 (pt) | acesso à memória por sistemas de processador duplo | |
| EP3618837A4 (en) | MULTI-DIRECTIONAL NUCLEOSIDE DERIVATIVES | |
| BR112016010635A2 (pt) | composto para tratamento de hipoglicemia severa | |
| EP3325564A4 (en) | AQUEOUS COATING COMPOSITION | |
| BR112018069440A2 (pt) | forma de dosagem oral | |
| EP3481379A4 (en) | ORAL GALENIC FORM CONTAINING A QUICK RELEASE EXTERIOR COATING | |
| BR112016006485A2 (pt) | composições de liberação pulsátil revestidas por compressão | |
| EP3233797A4 (en) | MAP4K4 (HGK) Inhibitors | |
| BR112014018149A8 (pt) | Composição melhorada de nitazoxadina e processo para preparar a mesma |